Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > OVs improve cancer immunotherapy by reprogramming TME

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Dec 11, 2023 11:23am

103 Views

Post# 35777862

RE:RE:RE:RE:RE:OVs improve cancer immunotherapy by reprogramming TME

Mcroots, show me the work that other OV companies have completed to prove their ability to remodel the TME, other than their rhetoric following the release of ONCYs clinical trial results on pelareoreps ability to convert an otherwise immunosuppressive TME and prime the TME in advance of CPI administration.

<< Previous

Bullboard Posts

Next >>

Cannara reports record growth and profitability in Q4 2023